LDLR and metabolic disease: The systemic administration of these exosomes in an Ldlr-deficient mouse model resulted in efficient uptake by hepatocytes and immune cells, the robust restoration of LDLR protein expression, and significant improvement to hypercholesterolemia and atherosclerosis phenotypes, illustrating the potential of exosome-mediated mRNA therapy in inherited metabolic diseases [90].